Alan Yager
Adolescent Medicine · Metairie, LANPI 1306941216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 306 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,196 and has fallen 59.1% since, to $489 in 2025. Among adolescent medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Bayer$960
- Boehringer Ingelheim$643
- Novo Nordisk$614
- Sanofi-aventis U.S. LLC$446
- Lilly USA, LLC$384
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,00299%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $1,196 |
| Bayer | 40 | $960 |
| Boehringer Ingelheim | 31 | $643 |
| Novo Nordisk | 36 | $614 |
| Sanofi-aventis U.S. LLC | 25 | $446 |
| Lilly USA, LLC | 17 | $384 |
| Amgen | 17 | $353 |
| Amarin Pharma, Inc. | 12 | $228 |
| Johnson & Johnson | 6 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $193 |
| Novartis | 9 | $158 |
| Pfizer | 6 | $111 |
| Astellas Pharma US Inc | 4 | $71 |
| Abbott | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| AbbVie | 3 | $45 |
| Exact Sciences | 2 | $42 |
| Merck | 3 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Edwards Lifesciences | 1 | $29 |
| Medtronic | 1 | $25 |
| Insulet Corporation | 1 | $22 |
| Mylan Specialty L.p. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,038 in reported general payments places this provider in the 95th percentile of 34 adolescent medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $155,682 |
| EliquisApixaban | 119 | $100,403 |
| FarxigaDapagliflozin Propanediol | 88 | $83,900 |
| JardianceEmpagliflozin | 78 | $67,311 |
| MounjaroTirzepatide | 58 | $63,235 |
| RybelsusSemaglutide | 36 | $42,403 |
| InvokanaCanagliflozin | 31 | $36,768 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 47 | $35,824 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $34,979 |
| KerendiaFinerenone | 30 | $31,366 |
| TrulicityDulaglutide | 28 | $27,244 |
| XareltoRivaroxaban | 20 | $26,419 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $26,347 |
| RexultiBrexpiprazole | 12 | $17,335 |
| JanuviaSitagliptin Phosphate | 29 | $16,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $614 | $207,169166 claims |
| PfizerEliquis | $111 | $100,403119 claims |
| AstraZenecaFarxiga, Symbicort | $1,196 | $91,772112 claims |
| Lilly USA, LLCMounjaro, Trulicity | $384 | $90,47986 claims |
| Boehringer IngelheimJardiance | $643 | $67,31178 claims |
| Johnson & JohnsonInvokana, Xarelto | $206 | $63,18751 claims |
| MerckJanumet Xr, Januvia | $40 | $52,62476 claims |
| BayerKerendia | $960 | $31,36630 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $446 | $13,15711 claims |
| AbbVieLinzess | $45 | $10,91019 claims |
| Astellas Pharma US IncMyrbetriq | $71 | $5,63313 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $4,252401 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 34 adolescent medicine providers in Louisiana.
Other adolescent medicine in Metairie
- Leslie BerHouma$4K
- Brannon PerillouxBaton Rouge$1K
- Nicole Kerley-McguireHouma$1K
- Robert BostickLuling$1K
- Tariq AhmedOlla$1K
- Quang VuHarvey$1K
- Robert DrummBaton Rouge$1K
- Rodger ElofsonBaton Rouge$949
- Robert ClarkeHouma$819
- Dana FakouriBaton Rouge$656
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.